Difference between revisions of "Nintedanib (Vargatef)"
Jump to navigation
Jump to search
(added package insert) |
|||
| Line 1: | Line 1: | ||
''Not FDA approved for an antineoplastic indication at this time.'' | ''Not FDA approved for an antineoplastic indication at this time.'' | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=504524 NCI Drug Dictionary]: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3). | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=504524 NCI Drug Dictionary]: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3).<ref name="insert">[https://pro.boehringer-ingelheim.com/products/vargatef/sites/default/files/2021-07/vargatef-epar-product-information_en.pdf Nintedanib (Vargatef) package insert]</ref><ref>[[:File:Nintedanib.pdf | Nintedanib (Vargatef) package insert (locally hosted backup)]]</ref><ref>[https://pro.boehringer-ingelheim.com/products/vargatef/ Vargatef manufacturer's website]</ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
*[[Ovarian cancer]] | *[[Ovarian cancer]] | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[https://pro.boehringer-ingelheim.com/products/vargatef/sites/default/files/2021-07/vargatef-epar-product-information_en.pdf Nintedanib (Vargatef) package insert]<ref>[https://pro.boehringer-ingelheim.com/products/vargatef/sites/default/files/2021-07/vargatef-epar-product-information_en.pdf Nintedanib (Vargatef) package insert]</ref> | ||
| + | *[https://www.uptodate.com/contents/nintedanib-patient-drug-information Nintedanib (Vargatef) patient drug information (UpToDate)]<ref>[https://www.uptodate.com/contents/nintedanib-patient-drug-information Nintedanib (Vargatef) patient drug information (UpToDate)]</ref> | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*11/21/2014: Initial marketing authorization as Vargatef. | *11/21/2014: Initial marketing authorization as Vargatef. | ||
| − | *Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy. | + | *Nintedanib (Vargatef) is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy. |
==Also known as== | ==Also known as== | ||
*'''Code name:''' BIBF 1120 | *'''Code name:''' BIBF 1120 | ||
*'''Brand names:''' Cyendiv, Idofnib, Nifev, Nindanib, Nintena, Nintenib, Nintib, Ofev, Vargatef | *'''Brand names:''' Cyendiv, Idofnib, Nifev, Nindanib, Nintena, Nintenib, Nintib, Ofev, Vargatef | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 00:15, 1 January 2022
Not FDA approved for an antineoplastic indication at this time.
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Multitargeted tyrosine kinase inhibitor BIBF 1120 selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration. In addition, this agent also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (fms-like tyrosine kinase 3).[1][2][3]
Diseases for which it is used
Patient drug information
- Nintedanib (Vargatef) package insert[4]
- Nintedanib (Vargatef) patient drug information (UpToDate)[5]
History of changes in EMA indication
- 11/21/2014: Initial marketing authorization as Vargatef.
- Nintedanib (Vargatef) is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.
Also known as
- Code name: BIBF 1120
- Brand names: Cyendiv, Idofnib, Nifev, Nindanib, Nintena, Nintenib, Nintib, Ofev, Vargatef